Relay Therapeutics 過去の業績

過去基準チェック /06

Relay Therapeuticsの収益は年間平均-15.4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.3% 9.1%割合で減少しています。

主要情報

-15.4%

収益成長率

55.5%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-9.1%
株主資本利益率	-41.2%
ネット・マージン	-3,449.9%
前回の決算情報	30 Sep 2024

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17

収支内訳

Relay Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:RLAY 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	10	-345	80	0
30 Jun 24	35	-323	79	0
31 Mar 24	35	-329	79	0
31 Dec 23	26	-342	79	0
30 Sep 23	26	-326	78	0
30 Jun 23	1	-344	75	0
31 Mar 23	1	-323	73	0
31 Dec 22	1	-291	69	0
30 Sep 22	2	-290	65	0
30 Jun 22	2	-267	66	0
31 Mar 22	2	-384	63	0
31 Dec 21	3	-364	60	0
30 Sep 21	85	-261	63	97
30 Jun 21	84	-414	58	97
31 Mar 21	84	-247	50	97
31 Dec 20	83	-230	42	0
30 Sep 20	0	-289	30	19
30 Jun 20	0	-95	21	37
31 Mar 20	0	-86	18	54
31 Dec 19	0	-75	17	67

質の高い収益: RLAYは現在利益が出ていません。

利益率の向上: RLAYは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RLAYは利益が出ておらず、過去 5 年間で損失は年間15.4%の割合で増加しています。

成長の加速: RLAYの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RLAYは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: RLAYは現在利益が出ていないため、自己資本利益率 ( -41.15% ) はマイナスです。

Relay Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Relay Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Relay Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Relay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000003 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Relay Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with Rly-2608

Consensus revenue estimates increase by 2,448%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

Relay Therapeutics, Inc., Annual General Meeting, Jun 03, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates decrease by 12%

Relay Therapeutics: Platform More Important Than Programs

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 10%

Relay Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

New major risk - Revenue and earnings growth

Relay Therapeutics, Inc. announced that it has received $30 million in funding

Relay Therapeutics, Inc. announced that it expects to receive $30 million in funding

Price target decreased by 7.1% to US$22.87

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 1,470%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Relay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Consensus revenue estimates decrease by 10%

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Relay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 8.4% to US$27.21

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.3% to US$29.04

Price target decreased by 12% to US$31.33

Consensus revenue estimates increase by 39%

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$670k worth of stock

Chief Legal Officer & Secretary notifies of intention to sell stock

High number of new directors

CEO, President & Director exercised options and sold US$660k worth of stock

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings released: US$0.76 loss per share (vs US$0.66 loss in 3Q 2021)

President of Research & Development exercised options and sold US$149k worth of stock

Relay Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

CEO, President & Director exercised options and sold US$711k worth of stock

President of Research & Development exercised options and sold US$146k worth of stock

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Relay Therapeutics, Inc. Presents Data at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Consensus revenue estimates fall by 20%

Why did Relay Therapeutics stock drop today?

President of Research & Development exercised options and sold US$153k worth of stock

President of Research & Development exercised options and sold US$313k worth of stock

Consensus forecasts updated

President of Research & Development exercised options and sold US$127k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Relay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Relay Therapeutics, Inc. Announces Appointment of Sekar Kathiresan to the Board

President of Research & Development exercised options and sold US$127k worth of stock

過去基準チェック /06